
News|Articles|July 9, 2007
Latebreakers: Once daily PAH drug OK'd
Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Accepts Sandoz Applications for Generic Tirzepatide
2
Making Medication Management Services Measurable and Visible
3
New ACIP Charter May Potentially Delay Vaccine Recommendations
4
Tech-Driven Home Pharmacy Model Tackles Rural Health Crises
5































